ABUS - アルブ―タス・バイオファ―マ (Arbutus Biopharma Corporation)

ABUSのニュース

   Altimmune Plans To Progress HepTcell But Market Shrugs It Off  2019-04-15
On April 12th, Altimmune ( ALT ) presented Phase I HepTcell data at the International Liver Congress in Vienna, Austria. Altimmune's immunotherapeutic synthetic peptide vaccine candidate demonstrated admirable safety and justified the company's plan to move into a Phase II study. Admittedly,…
   Altimmune Plans To Progress HepTcell But Market Shrugs It Off  2019-04-15
On April 12th, Altimmune ( ALT ) presented Phase I HepTcell data at the International Liver Congress in Vienna, Austria. Altimmune's immunotherapeutic synthetic peptide vaccine candidate demonstrated admirable safety and justified the company's plan to move into a Phase II study. Admittedly,…
   Altimmune Plans To Progress HepTcell But Market Shrugs It Off  2019-04-15
On April 12th, Altimmune ( ALT ) presented Phase I HepTcell data at the International Liver Congress in Vienna, Austria. Altimmune's immunotherapeutic synthetic peptide vaccine candidate demonstrated admirable safety and justified the company's plan to move into a Phase II study. Admittedly,…

calendar